BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1053 related articles for article (PubMed ID: 16146560)

  • 21. Hodgkin's lymphoma after post-transplant lymphoproliferative disease in a renal transplant recipient.
    Dharnidharka VR; Douglas VK; Hunger SP; Fennell RS
    Pediatr Transplant; 2004 Feb; 8(1):87-90. PubMed ID: 15009846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Case-control study of risk factors for the development of post-transplant lymphoproliferative disease in a pediatric heart transplant cohort.
    Katz BZ; Pahl E; Crawford SE; Kostyk MC; Rodgers S; Seshadri R; Proytcheva M; Pophal S
    Pediatr Transplant; 2007 Feb; 11(1):58-65. PubMed ID: 17239124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term follow-up of kidney transplant patients with posttransplant lymphoproliferative disorder: duration of posttransplant lymphoproliferative disorder-induced operational graft tolerance, interleukin-18 course, and results of retransplantation.
    Birkeland SA; Hamilton-Dutoit S; Bendtzen K
    Transplantation; 2003 Jul; 76(1):153-8. PubMed ID: 12865802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Lymphoproliferative disorders after renal transplantation in a child].
    Márquez U S; Peredo G MS; Vogel S A; Ibáñez A P
    Rev Med Chil; 2009 Mar; 137(3):405-10. PubMed ID: 19621184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
    Sundin M; Le Blanc K; Ringdén O; Barkholt L; Omazic B; Lergin C; Levitsky V; Remberger M
    Haematologica; 2006 Aug; 91(8):1059-67. PubMed ID: 16885046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients.
    Younes BS; McDiarmid SV; Martin MG; Vargas JH; Goss JA; Busuttil RW; Ament ME
    Transplantation; 2000 Jul; 70(1):94-9. PubMed ID: 10919581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of risk factors for the development of posttransplant lymphoprolipherative disorder among 119 children who received primary intestinal transplants at a single center.
    Quintini C; Kato T; Gaynor JJ; Ueno T; Selvaggi G; Gordon P; McLaughlin G; Tompson J; Ruiz P; Tzakis A
    Transplant Proc; 2006; 38(6):1755-8. PubMed ID: 16908272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Post-transplant lymphoproliferative disorders in liver transplanted patients: a single-centre experience.
    Marino D; Burra P; Boccagni P; Calabrese F; Canova F; Trentin C; Boso C; Soldà C; Angeli P; Aversa SM
    Anticancer Res; 2010 Jun; 30(6):2383-91. PubMed ID: 20651397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinico-pathological analysis of 6 cases of post-transplant lymphoproliferative disorders].
    Wang ZM; Zheng SS; Ding W; Wang LJ
    Zhonghua Xue Ye Xue Za Zhi; 2007 Aug; 28(8):514-8. PubMed ID: 18078125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation.
    Taylor AL; Bowles KM; Callaghan CJ; Wimperis JZ; Grant JW; Marcus RE; Bradley JA
    Transplantation; 2006 Aug; 82(3):375-81. PubMed ID: 16906036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence and consequences of post-transplantation lymphoproliferative disorders.
    Boubenider S; Hiesse C; Goupy C; Kriaa F; Marchand S; Charpentier B
    J Nephrol; 1997; 10(3):136-45. PubMed ID: 9238621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and pathological features of posttransplantation lymphoproliferative disorders presenting with skin involvement in 4 patients.
    Beynet DP; Wee SA; Horwitz SS; Kohler S; Horning S; Hoppe R; Kim YH
    Arch Dermatol; 2004 Sep; 140(9):1140-6. PubMed ID: 15381556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
    Trappe R; Riess H; Babel N; Hummel M; Lehmkuhl H; Jonas S; Anagnostopoulos I; Papp-Vary M; Reinke P; Hetzer R; Dörken B; Oertel S
    Transplantation; 2007 Apr; 83(7):912-8. PubMed ID: 17460562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience.
    Micallef IN; Chhanabhai M; Gascoyne RD; Shepherd JD; Fung HC; Nantel SH; Toze CL; Klingemann HG; Sutherland HJ; Hogge DE; Nevill TJ; Le A; Barnett MJ
    Bone Marrow Transplant; 1998 Nov; 22(10):981-7. PubMed ID: 9849695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
    Knight JS; Tsodikov A; Cibrik DM; Ross CW; Kaminski MS; Blayney DW
    J Clin Oncol; 2009 Jul; 27(20):3354-62. PubMed ID: 19451438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Post-transplant lymphoproliferative disorders in lung transplant recipients: 20-yr experience at the University of Minnesota.
    Wudhikarn K; Holman CJ; Linan M; Blaes AH; Dunitz JM; Hertz ME; Peterson BA
    Clin Transplant; 2011; 25(5):705-13. PubMed ID: 21077949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Posttransplant lymphoproliferative disorder after umbilical cord blood transplantation in children.
    Gong JZ; Bayerl MG; Sandhaus LM; Sebastian S; Rehder CW; Routbort M; Lagoo AS; Szabolcs P; Chiu J; Comito M; Buckley PJ
    Am J Surg Pathol; 2006 Mar; 30(3):328-36. PubMed ID: 16538052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation.
    Gross TG; Bucuvalas JC; Park JR; Greiner TC; Hinrich SH; Kaufman SS; Langnas AN; McDonald RA; Ryckman FC; Shaw BW; Sudan DL; Lynch JC
    J Clin Oncol; 2005 Sep; 23(27):6481-8. PubMed ID: 16170157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of pre-transplant Epstein-Barr virus (EBV) infection by donor blood transfusion in EBV-seronegative recipients may reduce risk of post-transplant lymphoproliferative disease in adolescent renal transplant patients: report of two cases.
    Babel N; Gabdrakhmanova L; Hammer M; Rosenberger C; Oppert M; Volk HD; Reinke P
    Transpl Infect Dis; 2005; 7(3-4):133-6. PubMed ID: 16390402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A single-centre experience of post-renal transplant lymphoproliferative disorder.
    Herzig KA; Juffs HG; Norris D; Brown AM; Gill D; Hawley CM; Cobcroft R; Petrie JB; Marlton P; Thomson D; Campbell SB; Nicol DL; Johnson DW
    Transpl Int; 2003 Jul; 16(7):529-36. PubMed ID: 12734646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.